Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Gynaecological cancers

3404 - Alienor/ENGOT-ov7 randomized trial exploring weekly Paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian Sex Cord tumors (SCT) in relapse

Date

19 Oct 2018

Session

Proffered paper session - Gynaecological cancers

Topics

Cytotoxic Therapy

Tumour Site

Ovarian Cancer

Presenters

Isabelle Ray-Coquard

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

I.L. Ray-Coquard1, P. Harter2, D. Lorusso3, C. Dalban1, I.B. Vergote4, K. Fujiwara5, L. Gladieff6, H. Lueck7, A. Floquet8, A.F. Lesoin9, A. Schnelzer10, S. Pignata11, F. Selle12, J. Sehouli13, F. Brocard14, G. Mangili15, P. Pautier16, U. De Giorgi17, M. Provansal18, P. Heudel19

Author affiliations

  • 1 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Gynecology & Gynecologic Oncology, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 3 Gynecologic Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4 Gynaecology, University Hospitals Leuven, 3000 - Leuven/BE
  • 5 Gynecologic Oncology, Saitama Medical University Internatl Medical Centre, 350-1298 - Saitama/JP
  • 6 Gynecologic Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 7 Gynecologic Oncology, Gynökologisch-onkologische Praxis, Hamburg/DE
  • 8 Oncologie Médicale, Institute Bergonié, 33076 - Bordeaux/FR
  • 9 Gynecologic Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 10 Oncologie Médicale, Klinikum rechts der Isar, 81675 - Munchen/DE
  • 11 Urology And Gynecology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 12 Medical Oncology, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 13 Gynecology, Department of Gynecology, Charité, Campus-Virchow-Klinikum, 13353 - Berlin/DE
  • 14 Oncologie Médicale, Centre d'Oncologie de Gentilly, 54100 - Nancy/FR
  • 15 Medical Oncology, Ospedale San Raffaele, 20132 - Milano/IT
  • 16 Medecine, Gustave Roussy, 94805 - Villejuif/FR
  • 17 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 18 Oncologie Médicale, Institut Paoli Calmettes, 13009 - Marseille/FR
  • 19 Oncologie Médicale, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3404

Background

Ovarian SCT tend to respond poorly to chemotherapy (CT). We explored the efficacy of wP with or w/o bev in a randomized 1:1 phase II trial in patients (pts) with relapse who were not candidate to surgery & after > 1 line of platinum based CT.

Methods

Primary endpoint is the PFS rate at 6 months (PFR-6). Pts in the wP arm were allowed to receive bev alone at progression. A Bayesian approach allowed continuous monitoring PFR-6 with sequential analyses planned every 20 pts to allow early stopping for efficacy. wP+Bev will be considered interesting if the probability is > 0.9 to show that the estimated PFR-6 in wP+Bev is higher than in wP arm.

Results

From 02/13 to 10/16, 60 pts with SCT (52 AGCT (Adult Granulosa cell tumor), 2 SLT (Sertoli Leydig tumor), 6 other) were randomized. All pts had recurrent disease and were previously treated with CT (47 pts received ≤2 lines). Baseline characteristics were well balanced between the 2 arms. 17 pts (28%) received prior hormonal therapy. Platinum-free interval (PFI) was ≥ 12 months in 21 pts (66%) and 22 (79%) in the wP and wP +bev group, respectively. The PFR-6 [95% CI] was 71% [55%; 84%] vs 72% [55%; 87%] in wP arm (arm A) and wP+bev (arm B). Median PFS were 14.7 and 14.9 months, in arm A and B respectively. In wP arm 50% of pts received bev alone at cross over, with median PFS of 7.3 months. Median TFST were 28.5, 33.6 and 33.6 months, in arm A + cross over bev, arm A w/o crossover and arm B respectively. Most frequent AE (all grade) were: hypertension in 78% of pts wP vs 93% of pts wP+Bev, fatigue (63% vs 78%), neuropathy (56% vs 74%), proteinuria (13% vs 63%), bleeding (16% vs 59%), alopecia (34% vs 56%), vomiting (16% vs 7%). Grade 3/4 AEs were reported in 10 arm wP vs 12 pts in arm wP+Bev.Table: 934O

ArmsORRSDPD
wP8(25%)17(53%)7(22%)
wP+Bev12(44%)12(44%)3(11%)

Conclusions

A randomized trial is feasible in rare cancer with a strong international collaboration. wP confirmed as active drug in SCT. Bev added to wP tends to increase ORR compared to wP alone but failed to significantly improve PFR-6 nor PFS in relapsed SCT pts.

Clinical trial identification

EudraCT: 2012-002841-39.

Legal entity responsible for the study

Michèle Torres-Macque.

Funding

Roche.

Editorial Acknowledgement

Thanks to all the patients and their families, the investigators, study nurses, pharmacists, pathologists and all study team.

Thanks to Roche laboratory for their financial support.

Disclosure

P. Harter: Honoraria: Roche, Astrazeneca, Tesaro; Consulting: Roche, AstraZeneca, Tesaro, Clovis, Pharmamar. I.B. Vergote: Consulting role: GCI Health, Oncoinvent AS, Rocje NV, Genmab A/S, Advaxis Inc, Morphotec Inc, F. Hoffmann-La Roche Ltd, Cerulean Pharma Inc, Novocure GMBH, AstraZeneca LP, Mateon Therapeutics Inc, Immunogen Inc, Eli Lilly benelux NV, Amgen INc, Theradex Europe Limited, Pfizer Inc, Debiopharma International SA, Vifor Pharma Belgie NV, Novartis Pharma AG, MSD Belgium BVBA, Oxigene Inc, Janssen-Cilag, Nektar Therapeutics, Bayer Pharma AG; Grant: Amgen, Roche; Travel accomodations: Tesaro, Theradex, Elsevier. K. Fujiwara: Honoraria: Chugai, Roche. L. Gladieff: Honoraria: AstraZeneca, Tesaro, Clovis, Roche; Travel accommodations: Roche, Pharmamar. H-J. Lueck: Honoraria: Tesaro, Roche, Amgen, AstraZeneca; Consulting: Tesaro, Roche, Pfizer, Novartis; Speakers' bureau: Roche, Novartis, Pfizer, Amgen; Travel accommodations: AstraZeneca, Tesaro. A. Floquet: Travel accommodations: Roche. A. Schnelzer: Consulting: Roche S. Pignata: Honoraria, Consulting, Travel accommodations: Roche. F. Selle: Consulting: MSD, Roche, AstraZeneca, Tesaro; Travel accommodations: MSD, Roche. J. Sehouli: Honoraria: Roche, AstraZeneca, Tesaro, Pharmamar; Consulting: Novartis, Clovis, Roche, AstraZeneca, Tesaro; Research fundings: Amgen, Novartis, Lilly, Bayer. G. Mangili: Speakers' bureau: Astrazeneca; Research fundings: Ipsen; Travel accommodations: Roche, PharmaMar. P. Pautier: Consulting role: Roche, Tesaro, AstraZeneca, Lilly. U. De Giorgi: Honoraria: BMS, AstraZeneca, Sanofi, Pfizer, Ipsen. P-E. Heudel: Consulting role: AstreZeneca, Pfizer, Novartis; Research fundings: AstrasZeneca; Travel and accommodation: Pfizer, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.